Association of matrix metalloproteinase-9 and nitric oxide with hypertension in obstructive sleep apnea

Shiying Zeng MD1 | Shisheng Li MD1 | Qinglai Tang MD1 | Ayinuer Tuerdi MD1 | Xinying Tong MM2 | Xiaojun Tang MD1 | Danhui Yin MD1 | Mengmeng Li MD1 | Qian Yang MM1

1Department of Otolaryngology, Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
2Nephrology Institute, Central South University, Changsha, Hunan, China

Correspondence
Shisheng Li, Second Xiangya Hospital, Central-South University, Changsha, 410011 Hunan, China.
Email: lissdoctor@csu.edu.cn

Funding information
National Natural Science Foundation of China, Grant/Award Number: 81870711; Natural Science Foundation of Hunan Province, Grant/Award Number: 2020JJ4791

Abstract

Background: Patients with obstructive sleep apnea (OSA) are more likely to suffer from hypertension. At the same time, the serum levels of matrix metalloproteinase-9 (MMP-9) and nitric oxide (NO) in patients with OSA are also changed in OSA patients. We investigated the correlation between serum levels of MMP-9, NO in patients with OSA and their association with hypertension in those patients, and the effects of continuous positive airway pressure therapy (CPAP) on these serum biomarkers and blood pressure.

Methods: Serum MMP-9 and NO levels and blood pressure of 57 patients with newly diagnosed OSA and 30 controls were measured; among them, 30 patients with moderate to severe OSA underwent 3-month CPAP treatment.

Results: In comparison to the control group, the MMP-9 serum levels were higher (232.8 ± 103.2 ng/ml versus 161.6 ± 56.5 ng/ml, \( p < .001^* \)), there was no statistical significance difference among serum NO (26.7 ± 9.1 IU/ml versus 31.0 ± 11.7 IU/ml, \( p = .06 \)), and MMP-9 was negatively correlated to NO, especially in patients with hypertension (\( r = -.644, p = .02^* \)). MMP-9, NO, and blood pressure were significantly recovered in the patients with OSA after CPAP treatment for 3 months (\( p < .05^* \)).

Conclusion: The MMP-9 level and the NO level were altered in OSA patients. The relationship between the two especially in patients with hypertension suggests the potential mechanism of OSA-induced hypertension.

KEYWORDS
blood pressure, CPAP, hypertension, MMP-9, NO, OSA

1 | INTRODUCTION

Obstructive sleep apnea (OSA) is a disease of apnea and hypopnea caused by upper airway collapse and obstruction during sleep, often accompanied by acute autonomic and hemodynamic disruptions. With these features, the OSA patients gradually develop obvious arterial hypercapnia and hypoxemia.1 Currently, OSA is considered to be a public disease with high morbidity in both adults and children.2

Laryngoscope Investigative Otolaryngology. 2022;7:885–893. wileyonlinelibrary.com/journal/lio2

885
Researchers believe that OSA is a risk factor for many cardiovascular diseases, including hypertension.\textsuperscript{3,4} The epidemiologic association between OSA and cardiovascular diseases could be attributed to many factors, like nocturnal intermittent hypoxemia, hypercapnia, highly active sympathetic nervous system, change of intrathoracic pressure, endothelial dysfunction, metabolic anomalies, and systemic inflammation.\textsuperscript{3,5,6} It is reported that the blood pressure of patients with OSA can be significantly improved after continuous positive airway pressure ventilation (CPAP).\textsuperscript{7} The specific pathophysiological mechanism between OSA and hypertension is unclear. The importance of oxidative stress and inflammation in OSA has been stressed by tons of studies\textsuperscript{8} and the changes of cytokines or their combinations in OSA patients have been getting increasing attention.\textsuperscript{9} Finding out which inflammatory factors are changed in OSA and whether alterations of these inflammatory factors are inter-correlated could be clinically significant.

Matrix metalloproteinase-9 (MMP-9) is a member of the zinc-metalloproteinase family. It is involved in the degradation of proteins in extracellular matrix (ECM) in many normal physiological processes and disease processes.\textsuperscript{10} It is reported that the level of activity of MMP-9 was changed in cardiovascular diseases and other pathological backgrounds.\textsuperscript{11} Patients with hypertension express higher serum levels of MMP-9.\textsuperscript{12} In addition, studies have shown that the serum level and activity of MMP-9 were increased in patients with OSA.\textsuperscript{13,14} Our previous study found that level of MMP-9 was positively correlated with the severity of OSA and the degree and duration of hypoxia.\textsuperscript{15} Cell experiments showed that the inhibitor of nitric oxide (NO) and nitric oxide synthase (NOS) could enhance the expression of MMP-9.\textsuperscript{16,17} NO is a physiologically related gasotransmitter that can regulate blood pressure and vascular function.\textsuperscript{18} The effect of NO on the heart could be a universal defense against ischemia–reperfusion.\textsuperscript{19} Decreased plasma concentration of NO and NO metabolites has been thought to be associated with cardiovascular events.\textsuperscript{20,21} And the plasma levels of nitric oxide derivative\textsuperscript{22} and endothelial nitric oxide synthetase (eNOS)\textsuperscript{23} were downregulated in OSA patients. Although the two cytokines are altered in OSA patients and were separately reported to be associated with hypertension, the correlation between the four has not been studied, which is also the purpose of this article.

**FIGURE 1** Subject enrollment and study design

323 Patients were assessed for eligibility

- 77 did not meet the inclusion criteria
- 152 had one or more exclusion criteria

94 individuals entering into study

- 3 missing sleep study
- 4 declined to participate

87 completed all procedure

57 OSA patients, among them,
- 15 with hypertension,
- 42 without hypertension.

30 controls, among them,
- 12 with hypertension,
- 18 without hypertension.

30 received 3months CPAP treatments.
2 | MATERIALS AND METHODS

2.1 Participants

The study recruited 87 participants who complained of snoring, with ages ranging from 19 to 64 years old (see Figure 1). The inclusion criteria were no CPAP therapy or surgery therapy for OSA. Exclusion criteria for all subjects included a history of smoking or alcoholism and previous or current treatment for cardiovascular disease, stroke, severe renal insufficiency, severe lung disease, acute infection, trauma, taking medications for hypertension, diabetes mellitus, or dyslipidemia or surgeries 1 month before the study. Among the 87 patients, 57 patients with apnea–hypopnea index (AHI) ≥ 5 were defined as the OSA group, 30 patients with AHI <5 were defined as the control group. The study was approved by the ethics committee of the Second Xiangya Hospital (No.2019001), Central South University in China, and all patients gave written informed consent.

2.2 Polysomnography

All participants received standard nighttime polysomnography (EMBLA; Flagra high frequency. Medical Devices, Reykjavik, Iceland). OSA is defined as the AHI≥5 events per hour, with the severity

| TABLE 1 Baseline characteristics in patients with OSA and control subjects |
|-----------------------------|-----------------------------|-----------------------------|
|                            | Patients with OSA (n = 57)  | Healthy subjects (n = 30)   |
| Age (years)                 | 42.3 ± 10.6                 | 44.1 ± 10.5                 |
| BMI (kg/m²)                 | 27.5 ± 3.8                  | 27.0 ± 3.8                  |
| AHI (events/h)              | 44.0 ± 20.1                 | 2.9 ± 1.2                   |
| Lower nadir SaO₂ (%)        | 67.5 ± 11.0                 | 85.8 ± 3.5                  |
| CT90 (%)                    | 31.9 ± 24.1                 | 1.0 ± 1.2                   |
| Systolic pressure (mmHg)    | 117.7 ± 24.1                | 123.9 ± 25.2                |
| Diastolic pressure (mmHg)   | 75.4 ± 14.7                 | 81.7 ± 16.5                 |
| ESS                         | 12.7 ± 4.5                  | 5.4 ± 2.8                   |
| NO (IU/ml)                  | 26.7 ± 9.1                  | 31.0 ± 11.7                 |
| MMP-9 (ng/ml)               | 232.8 ± 103.2               | 161.6 ± 56.5                |
| Male/female (n)             | 52/5                       | 26/4                       |

Note: *p < .05.

Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index; CT90, a greater percentage of sleep time when blood oxygen saturation is less than 90%; ESS, Epworth Sleepiness Scale; LSaO₂, lowest saturation oxygen; MMP-9, matrix metalloproteinase-9; NO, nitric oxide synthetase; SaO₂, saturation oxygen.

| TABLE 2 Parameters in patients with mild to moderate OSA compared with those with severe OSA |
|-----------------------------|-----------------------------|-----------------------------|
|                            | Mild to moderate (n = 18)   | Severe (n = 39)             |
| Age (years)                 | 34.1 ± 10.1                 | 45.7 ± 8.7                  |
| BMI (kg/m²)                 | 26.2 ± 3.4                  | 28.2 ± 3.9                  |
| AHI (events/h)              | 20.3 ± 7.8                  | 54.9 ± 13.5                 |
| Lower nadir SaO₂ (%)        | 77.7 ± 5.9                  | 62.8 ± 9.5                  |
| CT90 (%)                    | 9.6 ± 8.0                   | 42.3 ± 22.0                 |
| Systolic pressure (mmHg)    | 109.3 ± 17.5                | 121.6 ± 25.9                |
| Diastolic pressure (mmHg)   | 70.7 ± 9.8                  | 77.6 ± 16.2                 |
| ESS                         | 12.3 ± 4.4                  | 12.8 ± 4.6                  |
| NO (IU/ml)                  | 31.5 ± 7.3                  | 24.4 ± 9.1                  |
| MMP-9 (ng/ml)               | 199.8 ± 89.2                | 248.0 ± 106.7               |
| Male/female (n)             | 16/2                       | 36/3                       |

Note: *p < .05.

Abbreviations: AHI, apnea–hypopnea index; BMI, body mass index; CT90, a greater percentage of sleep time when blood oxygen saturation is less than 90%; ESS, Epworth Sleepiness Scale; LSaO₂, lowest saturation oxygen; MMP-9, matrix metalloproteinase-9; NO, nitric oxide synthetase; SaO₂, saturation oxygen.
described as mild for an AHI score of 5 to less than 15 (5 ≤ AHI < 15), moderate for an AHI score of 15 to 30 (15 ≤ AHI < 30), and severe for an AHI score of more than 30 (AHI ≥ 30).

2.3 | Blood pressure measurement

The blood pressure (BP) of all participants was measured by periodically calibrated mercury sphygmomanometer the next morning after the PSG test. A cuff of appropriate size was applied on the nondominant arm. A trained nurse measured the BP and heart rate of participants three times at 5-min intervals after 15 min of resting in a seated position. The average of three measurements was adopted.

2.4 | Medication history in the “past” 1 year

Through the questionnaire, we collected some general information including medical history, family history, smoking or drinking habits, operation history, and medication history in recent 1 year. Excessive daytime somnolence was assessed by the Epworth Sleepiness Scale (ESS).

2.5 | Measurement of NO and MMP-9

Blood samples were collected the morning following the PSG test, immediately centrifuged to collect plasma/serum, frozen at −80°C, and finally analyzed by enzyme-linked immunosorbent assay (ELISA). The ELISA Kit for MMP-9 (ELISA, R&D Systems, Inc.) was used to quantify MMP-9 levels in the serum of OSA patients. NO concentrations were determined using (R&D Systems, Catalog #KGE001, Inc.). This kit determines NO concentrations based on the enzymatic conversion of nitrate to nitrite by nitrate reductase. After the reaction, the nitrite as the product of azo dye in Griess reaction was detected by colorimetry.

2.6 | CPAP treatment

After diagnostic studies, patients with moderate to severe OSA (AHI > 15 events/h) received a treatment of CPAP during the next...
3 months. Nasal CPAP titration using a commercial CPAP device (Philips, Respironics), which was performed to abolish apnea and snoring completely and to maintain SaO₂ >90% during sleep, and the optimal CPAP level was determined.

2.7 | Statistical analysis

IBM SPSS software 23 ([https://www.ibm.com/products/spss-statisticsRRID:SCR_019096](https://www.ibm.com/products/spss-statistics)) was used for data processing. Measurement data or classified data are respectively represented by mean ± standard deviation (SD), number, or percentage. The normal distribution was verified by Kolmogorov–Smirnov test. Student’s t test, Mann–Whitney test, and χ² test were used to compare the variables. Differences of values before and after CPAP were compared using a two-tailed paired Wilcoxon test or Wilcoxon signed-rank test. The correlation of variables was tested by Spearman’s rank. With regard to the relative strength of association of serum levels of MMP-9 and NO, stepwise multiple regression analysis was applied to patients with OSA as a single group. When \( p < .05 \), the difference was considered to be statistically significant.

### TABLE 4 Parameter changes of OSA patients before and after treatment

| Parameter                        | preCPAP OSA (n = 30) | postCPAP (n = 30) | Difference value | \( p \) |
|---------------------------------|----------------------|-------------------|------------------|-------|
| Systolic pressure (mmHg)       | 127.6 ± 26.0         | 118.5 ± 19.5      | 8.8 ± 17.3       | .007* |
| Diastolic pressure (mmHg)      | 81.6 ± 16.1          | 72.4 ± 12.0       | 8.1 ± 10.9       | <.001*|
| ESS                             | 13.3 ± 4.5           | 7.1 ± 2.5         | 6.2 ± 4.6        | <.001*|
| NO (IU/ml)                      | 25.6 ± 9.9           | 33.3 ± 9.0        | −7.8 ± 7.9       | <.001*|
| MMP-9 (ng/ml)                   | 251.3 ± 106.8        | 160.8 ± 96.5      | 87.4 ± 91.2      | <.001*|

Note: "\( p < .05 \)."

Abbreviations: ESS, Epworth Sleepiness Scale; MMP-9, matrix metalloproteinase-9; NO, nitric oxide.

### FIGURE 3 The changes of systolic pressure (A), diastolic pressure (B), ESS (C), MMP-9 (D), and NO (E) before and after treatment
3 | RESULTS

3.1 | Subject characteristics

The basic characteristics of all participants are shown in Table 1. Age, body mass index (BMI), blood pressure, and gender composition between two groups is of no statistical significance. Compared to the participants in the control group, the OSA patients have a higher AHI, lower nadir Arterial Oxygen Saturation (SaO2), a greater percentage of sleep time when blood oxygen saturation is less than 90% (CT90), and higher ESS. Most importantly, OSA patients have a higher serum concentration of MMP-9 (232.8 ± 103.2 ng/ml versus 161.6 ± 56.5 ng/ml, p < .001*), but there was no statistical difference in concentration of serum NO (26.7 ± 9.1 IU/ml vs. 31.0 ± 11.7 IU/ml p = .06).

3.2 | Effect of the severity of OSA on NO and MMP-9 expression

Based on AHI, the OSA group was further divided into mild to moderate group (5 < AHI < 30) and severe group (AHI ≥ 30), and the results are shown in Table 2, the values of AHI in the two groups were 20.3 ± 7.8 events/h and 54.9 ± 13.5 events/h, respectively. There were no significant differences in gender composition, BMI, diastolic blood pressure, and ESS between the two groups. Patients with severe OSA are older than mild to moderate patients, which may be related to the development of OSA. And there was a tendency of increased overweight severity (p = .07) in the severe group, these results can be explained as follows obesity is a risk factor for OSA, and severe OSA patients had a higher systolic pressure (p = .04*). Patients with severe OSA had a significantly lower serum level of NO (p = .006*); however, there was no significant difference in the serum level of MMP-9 (p = .10).

3.3 | Correlation between NO and MMP-9 and clinical parameters and their relationship in OSA

Spearman’s rank correlation coefficients between serum levels of NO or MMP-9 and various parameters in patients with OSA (n = 57) are shown in Table 3. We can see that NO is related to AHI, and MMP-9 is correlated with age and blood pressure, both of them are related to the lowest blood oxygen and CT90. There is also a correlation between MMP-9 and NO.

According to whether the OSA patients complained of hypertension, we divided them into the following two groups: OSA with hypertension (n = 15), OSA without hypertension (n = 42). Interestingly, we analyzed the correlation of MMP-9 and NO between the two in OSA with hypertension and OSA without hypertension, OSA patients with hypertension show a relatively strong correlation, although there is no significant correlation between them in OSA patients without hypertension (Figure 2).

3.4 | The effects of CPAP treatment on OSA patients

In 57 OSA patients, 30 patients were treated with CPAP. The data comparison before and after treatment is shown in Table 4. The MMP-9, NO, blood pressure, ESS in OSA patients were statistically significantly changed after treatment, reflecting that CPAP can alleviate or even reverse these parameters. Changes in data are illustrated in Figure 3.

4 | DISCUSSION

OSA has been getting increasing awareness among the public in recent years, and it is recognized that OSA could cause cardiovascular diseases such as hypertension. Meanwhile, 30%–83% of hypertension patients have got OSA. Therefore, it is of great clinical significance for the prevention and treatment of OSA and hypertension to understand the underlying mechanism of OSA. Our study has found that severe OSA patients suffered elevated blood pressure. CPAP therapy can partially reverse hypertension in OSA patients, and this is consistent with the previous results. However, the specific mechanism of OSA leading to cardiovascular diseases such as hypertension is not clear. Regarding MMP-9 and NO in OSA patients, our study showed that they have a certain correlation in OSA patients especially patients with hypertension. To the best of our knowledge, this is the first study to evaluate the relationship between MMP-9 and NO levels and hypertension in OSA patients.

Our study showed a higher serum MMP-9 level in OSA patients, and the MMP-9 is correlated with blood pressure. MMPs contain more than 20 subtypes, of which MMP-2 and MMP-9 have been mentioned in OSA-related studies. Our previous study and meta-analysis have shown that the peripheral level of MMP-9 was increased in OSA patients, which was related to the severity of OSA. MMPs were up-regulated by inflammatory cytokines. OSA provides such an inflammatory and hypoxia environment. Our previous studies also found that the serum level of MMP-9 in OSA patients was increased and associated with hypertension and left ventricular hypertrophy. Furthermore, it has been proved that activation of MMP-9 preceded left ventricular remodeling in hypertensive heart failure in a rat model. Studies had found that the increase of MMP-9 could contribute to the change of cardiac structure and function, and may be involved in atherosclerosis, which is associated with elevated blood pressure. Stiffening and extracellular matrix remodeling of arteries is associated with an increased cardiovascular risk. MMP-9 has been reported to degrade elastin and collagen. Elastin provides the main elastic element of arteries. Therefore MMP-9 is thought to be involved in destruction of the arterial media and various heart diseases. Moreover, targeted deletion of the MMP-9 attenuates collagen accumulation suggesting that MMP-9 plays a prominent role in extracellular matrix remodeling. Over time, collagen deposition in cardiovascular diseases also leads to the increase of MMP-9 level. In OSA-related hypertension, the increase of MMP-9 level may be a vicious cycle. Although our study demonstrated that serum MMP-9
levels in patients with OSA were higher than those in control, there was no significant difference between patients with severe OSA and patients with mild to moderate OSA. This result may be related to population imbalance, and more patients with mild to moderate OSA should be included in the study.

In our study, although there is not a significant difference in serum NO between OSA and control participants, the NO level was lower in patients with severe OSA. NO is synthesized under the action of NO synthase (NOS), which occur in three isoforms: endothelial (eNOS), inducible (iNOS), and neuronal (nNOS). eNOS is the enzyme responsible for NO production in vascular. And chronic intermittent hypoxia (CIH) led to eNOS uncoupling in mice model and OSA patients, and inhibit eNOS at RNA level. So, the relationship interaction and hypertension was discussed in OSA patients first. Our results might be conducive to the prevention and treatment of obstructive sleep apnea syndrome and its related hypertension. There are also some limitations in our research. First, relatively few patients were included in the study. Second, the dynamic changes of NO and MMP-9 were not observed during the follow-up period. We only observed the correlation between MMP-9 and NO in this clinical observational study, the causality between them needs to be verified by subsequent in vitro mechanism studies and relevant animal experiments. Finally, the process of OSA-induced hypertension is a very complex pathophysiological process, which many other serum biomarkers may also involve. Further analysis of other biomarkers would help to understand its pathogenesis.

5 | CONCLUSION

In summary, we have shown that the levels of MMP-9 are elevated in OSA patients and may have an effect on lowering NO levels, particularly in patients with hypertension. These changes can be reversed by CPAP therapy. The correlation between MMP-9 and NO in OSA patients especially in patients with hypertension suggests a potential underlying mechanism for the association between hypertension and OSA.

ACKNOWLEDGMENTS

This research was supported by the National Natural Science Foundation of China (no. 81870711) and the Natural Science Foundation of Hunan Province (no. 2020JJ4791).

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Shiying Zeng: conception, data collection, analysis, interpretation, drafting. Shisheng Li: conception, analysis, interpretation, revision, approval. Qinglai Tang: conception, revision, approval. Ayinuer Tuerdi: conception, revision. Xinying Tong: analysis, interpretation, drafting. Xiaojun Tang: data collection, analysis, drafting. Danhui Yin: data collection, analysis; Mengmeng Li: data collection, analysis. Qian Yang: data collection, analysis.

ORCID

Shiying Zeng https://orcid.org/0000-0002-6609-5175
Shisheng Li https://orcid.org/0000-0001-5874-6049
Qinglai Tang https://orcid.org/0000-0002-1246-182X
Qian Yang https://orcid.org/0000-0002-9939-5131

REFERENCES

1. Basner RC. Cardiovascular morbidity and obstructive sleep apnea. N Engl J Med 2014;370:2339-2341.
2. Cao C, Wu B, Wu Y, et al. Functional polymorphisms in the promoter region of MMP-2 and MMP-9 and susceptibility to obstructive sleep apnea. Sci Rep 2015;5:8966.
1. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373:82-93.

2. Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA. 2012;307:2169-2176.

3. Miller JD, Aronis KN, Chrispin J, et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol. 2015;66:2899-2906.

4. Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pépin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol. 2012;9:679-688.

5. Gottlieb DJ, Punjabi NM, Mehra R, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med. 2014;370:2276-2285.

6. Tan J, Hua Q, Xing X, et al. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30:959-963.

7. Tazaki T, Minoguchi K, Yokoe T, et al. Increased levels and activity of Chuang LP, Chen NH, Lin SW, Chang YL, Chao IJ, Pang JHS.

8. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Circ Chim Acta. 2012;413:656-662.

9. Leon-Cabrera S, Arana-Lechuga Y, Esqueda-León E, et al. Reduced systemic levels of IL-10 are associated with the severity of obstructive sleep apnea and insulin resistance in morbidly obese humans. Mediators Inflamm. 2015:2015:493409.

10. Nagase H, Woesner JR Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.

11. Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012;413:656-662.

12. Tan J, Hua Q, Xing X, et al. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30:959-963.

13. Tazaki T, Minoguchi K, Yokoe T, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2004;170:1354-1359.

14. Chuang LP, Chen NH, Lin SW, Chang YL, Chao IJ, Pang JHS. Increased matrix metalloproteinases-9 after sleep in plasma and in monocytes of obstructive sleep apnea patients. Life Sci. 2013;93:220-225.

15. Wang S, Li S, Wang B, Liu J, Tang Q. Matrix Metalloproteinase-9 is a predictive factor for systemic hypertension and heart dysfunction in patients with obstructive sleep apnea syndrome. Biomed Res Int. 2018;2018:1569701.

16. Upchurch GR Jr, Ford JW, Weiss SJ, et al. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg. 2001;34:76-83.

17. Knipp BS, Allawadi G, Ford JW, et al. Increased MMP-9 expression and activity by aortic smooth muscle cells after nitric oxide synthase inhibition is associated with increased nuclear factor-kappaB and activation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-276.

18. Javaheri S, Barfe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841-858.

19. Noda A, Nakata S, Koike Y, et al. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. J Hypertens. 2007;25:372-378.

20. Kostov K, Halacheva L. Role of magnesium deficiency in promoting atherosclerosis, endothelial dysfunction, and arterial stiffening as risk factors for hypertension. Int J Mol Sci. 2018;19:1724.

21. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol. 2004;286:H1-H10.

22. Skjat-Arkil H, Clausen RE, Nguyen QH, et al. Measurement of MMP-9 and -12 degradation elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med. 2012;12:34.

23. Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-276.

24. Yon B, Liu Y, Chen J, et al. Vascular peroxynitrite 1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation, apoptosis resistance and migration. Cardiovasc Res. 2018;114:188-199.

25. Simon B, Barta I, Gabor B, et al. Effect of 5-year continuous positive airway pressure treatment on MMPs and TIMPs: implications for OSA comorbidities. Sci Rep. 2020;10:8609.

26. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation. 2004;109:2143-2149.

27. Hultman E, Malm S, Hedin U, et al. Nitric oxide metabolites and erythrocyte deformability in a group of patients with obstructive sleep apnea syndrome. Clin Sci (Lond). 2009;33:1467-1484.

28. Javaheri S, Barfe F, Campos-Rodriguez F, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69:841-858.

29. Franczak A, Bil-Lula I, Sawicki G, Fenton M, Ayas N, Skomro R. Matrix metalloproteinases as possible biomarkers of obstructive sleep apnea severity - a systematic review. Sleep Med Rev. 2019;46:9-16.

30. Fang X, Chen J, Wang W, et al. Matrix metalloproteinase 9 (MMP9) level and MMP9 -1562C>T in patients with obstructive sleep apnea: a systematic review and meta-analysis of case-control studies. Sleep Med. 2020;67:110-119.

31. Jones SP, Bolli R. The ubiquitous role of nitric oxide in obstructive sleep apnea syndrome. J Mol Cell Cardiol. 2006;40:16-23.

32. Noda A, Nakata S, Koike Y, et al. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. Hypertens Res. 2007;30:669-676.

33. Alonso-Fernández A, García-Río F, Arias MA, et al. Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax. 2009;64:581-586.

34. Schulz R, Schmidt D, Blum A, et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax. 2000;55:1046-1051.

35. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation. 2008;117:2270-2278.
44. Zhang D, Xiao Y, Luo J, et al. Measurement of fractional exhaled nitric oxide and nasal nitric oxide in male patients with obstructive sleep apnea. Sleep Breath. 2019;23:785-793.

45. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia – revisited – the bad ugly and good: implications to the heart and brain. Sleep Med Rev. 2015;20:27-45.

46. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med. 1992;327:669-677.

47. Eagleton MJ, Peterson DA, Sullivan VV, et al. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression. J Surg Res. 2002;104:15-21.

48. Eberhardt W, Akool EL, Rebhan J, et al. Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor alpha agonists is indirect and due to a NO-mediated reduction of mRNA stability. J Biol Chem. 2002;277:33518-33528.

49. O’Sullivan S, Medina C, Ledwidge M, et al. Nitric oxide-matrix metalloproteinase-9 interactions: biological and pharmacological significance. Biochim Biophys Acta. 2014;1843:603-617.

50. Ridnour LA, Windhausen AN, Isenberg JS, et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A. 2007;104:16898-16903.

51. Sapin-Seltrán E, Benitez ID, Torres G, et al. Effect of CPAP treatment on BP in resistant hypertensive patients according to the BP dipping pattern and the presence of nocturnal hypertension. Hypertens Res. 2021;45:436-444.

How to cite this article: Zeng S, Li S, Tang Q, et al. Association of matrix metalloproteinase-9 and nitric oxide with hypertension in obstructive sleep apnea. Laryngoscope Investigative Otolaryngology. 2022;7(3):885-893. doi:10.1002/lio2.796